The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.

The present invention relates to multispecific antibodies against a novel targets' combination of HVEM and CD9, and their use in the treatment of cancer and infectious diseases.

Provided are CD8 binding agents comprising a VHH domain that specifically binds human CD8. Also provided are nucleic acids encoding such CD8 binding agents, vectors comprising such nucleic acids, host cells comprising same, and methods of making such CD8 binding agents. Also provided are CD8 binding agents having the VHH domain conjugated to a detectable label. Provided are methods of using such CD8 binding agents to detect CD8+ T cells, monitor disease progress, and monitor treatment progress in a subject having cancer, autoimmune disease or condition, transplant rejection or graft-versus-host disease.

The present disclosure provides an anti-PD-L1/anti-B7-H3 multispecific antibody capable to effectively block the interaction between PD-L1 and its receptor PD-1, and suppress the T-cell inhibitory effect of B7-H3 protein. The multispecific antibody may have high binding affinity to both of a PD-L1 protein and a B7-H3 protein.

The present invention relates to a bispecific antibody against CLDN18.2 and CD3. The bispecific antibody effectively binds to CLDN18.2 and CD3 antigens.

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.

The present invention relates to antibodies having specificity for BTLA and uses thereof, in particular for the treatment of cancer.

Among the various aspects of the present disclosure is the provision of methods and compositions for reducing checkpoint immunotherapy resistance or enhance checkpoint immunotherapy efficacy comprising treatment with a TREM2 inhibiting agent having reduced Fc effector function.

The present invention relates to methods for the selective expansion of γδ T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched γδ T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.